However, combinational treatment of paclitaxel and PERK inhibitor could further sensitize the tumor of the 4A-mutant cells, but had less effect on the tumor from cells expressing wild-type viral oncogenes (Fig. 8b–d and f–h, Supplementary Figure 7c and d). This evidence concerns the gene EIF2AK3 and neoplasm.